Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

Uroxatral (alfuzosin) may not only help BPH symptoms but may also improve sexual function in males with BPH and ED.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospitals Cleveland Medical Center
• Collaborator: Sanofi
• Treatments: Alfuzosin

Criteria

Inclusion Criteria:

• Males 45-75 years of age

• Confirmed diagnosis of BPH/lower urinary tract symptoms (LUTS) and ED

• Men with steady partner and who agree to attempt sex once a week.

Exclusion Criteria:

• Prostate cancer

• Prostatitis

• Penile disease

• Cardiac co-morbidity

• Pre-existing co-morbid conditions

• History of sensitivity to the drug or similar drugs

• Enrollment in another clinical trial

• Impaired hepatic function

• Impaired renal function

• Mental conditions rendering subject unable to understand the study

• Subjects not likely to comply with protocol